{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T14:30:54Z","timestamp":1648737054485},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,12,24]],"date-time":"2008-12-24T00:00:00Z","timestamp":1230076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1007\/s11899-009-0001-x","type":"journal-article","created":{"date-parts":[[2008,12,23]],"date-time":"2008-12-23T06:33:28Z","timestamp":1230014008000},"page":"3-9","source":"Crossref","is-referenced-by-count":5,"title":["Management of myelodysplastic syndromes in the geriatric patient"],"prefix":"10.1007","volume":"4","author":[{"given":"Ellen K.","family":"Ritchie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark S.","family":"Lachs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,12,24]]},"reference":[{"key":"1_CR1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","volume":"112","author":"D.E. Rollison","year":"2008","unstructured":"Rollison DE, Howlader N, Smith MT, et al.: Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States 2001\u20132004, using data from the NAACCR and SEER programs. Blood 2008, 112:45\u201352.","journal-title":"Blood"},{"key":"1_CR2","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1182\/blood-2004-05-1812","volume":"104","author":"J.M. Guralnik","year":"2004","unstructured":"Guralnik JM, Eisenstaedt RS, Ferrucci L, et al.: Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004, 104:2263\u20132268.","journal-title":"Blood"},{"key":"1_CR3","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1182\/blood.V98.8.2326","volume":"98","author":"T. Witte de","year":"2001","unstructured":"de Witte T, Suciu S, Verhoef G, et al.: Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 2001, 98:2326\u20132331.","journal-title":"Blood"},{"key":"1_CR4","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P. Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079\u20132088.","journal-title":"Blood"},{"key":"1_CR5","first-page":"3671","volume":"96","author":"B.D. Cheson","year":"2000","unstructured":"Cheson BD, Bennett JM, Kantarjian H, et al.: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000, 96:3671\u20133674.","journal-title":"Blood"},{"key":"1_CR6","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","volume":"25","author":"L. Malcovati","year":"2007","unstructured":"Malcovati L, Germing U, Kuendgen A, et al.: Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503\u20133510.","journal-title":"J Clin Oncol"},{"key":"1_CR7","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1038\/sj.leu.2403963","volume":"19","author":"U. Germing","year":"2005","unstructured":"Germing U, Hildebrandt B, Pfeilst\u00f6ker M, et al.: Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 2005, 19:2223\u20132231.","journal-title":"Leukemia"},{"key":"1_CR8","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.leu.2405070","volume":"22","author":"G. Garcia-Manero","year":"2008","unstructured":"Garcia-Manero G, Shan J, Faderl S, et al.: A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008, 22:538\u2013543.","journal-title":"Leukemia"},{"key":"1_CR9","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/cncr.23697","volume":"113","author":"H. Kantarjian","year":"2008","unstructured":"Kantarjian H, O\u2019Brien S, Ravandi F, et al.: Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008, 113:1351\u20131361.","journal-title":"Cancer"},{"key":"1_CR10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/j.seminhematol.2008.06.005","volume":"45","author":"P.H. Chaves","year":"2008","unstructured":"Chaves PH: Functional outcomes of anemia in older adults. Semin Hematol 2008, 45:255\u2013260.","journal-title":"Semin Hematol"},{"key":"1_CR11","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","volume":"56","author":"L.P. Fried","year":"2001","unstructured":"Fried LP, Tangen CM, Walston J, et al.: Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001, 56:M146\u2013M156.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1_CR12","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1001\/archinte.165.19.2214","volume":"165","author":"N.A. Zakai","year":"2005","unstructured":"Zakai NA, Katz R, Hirsch C, et al.: A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. Arch Intern Med 2005, 165:2214\u20132220.","journal-title":"Arch Intern Med"},{"key":"1_CR13","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1111\/j.1532-5415.2004.52502.x","volume":"52","author":"P.H. Chaves","year":"2004","unstructured":"Chaves PH, Xue QL, Guralnik JM, et al.: What constitutes normal hemoglobin concentration in community-dwelling disabled older women? J Am Geriatr Soc 2004, 52:1811\u20131816.","journal-title":"J Am Geriatr Soc"},{"key":"1_CR14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2141.2003.03907.x","volume":"120","author":"D. Bowen","year":"2003","unstructured":"Bowen D, Culligan D, Jowitt S, et al.: Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003, 120:187\u2013200.","journal-title":"Br J Haematol"},{"key":"1_CR15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1046\/j.1365-2141.2003.04272.x","volume":"121","author":"A.J. Jansen","year":"2003","unstructured":"Jansen AJ, Essink-Bot ML, Beckers EA, et al.: Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol 2003, 121:270\u2013274.","journal-title":"Br J Haematol"},{"key":"1_CR16","first-page":"440a","volume":"110","author":"A.F. List","year":"2007","unstructured":"List AF, Baer MR, Steensma D, et al.: Deferasirox (ICL670; Exjade) reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndrome [abstract 1470]. Blood (ASH Annual Meeting Abstracts) 2007, 110:440a.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"1_CR17","first-page":"80a","volume":"110","author":"C. Rose","year":"2007","unstructured":"Rose C, Brechignac S, Vassilief D, et al.: Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients; a prospective analysis by the GFM [abstract 249]. Blood (ASH Annual Meeting Abstracts) 2007, 110:80a.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"1_CR18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.1995.tb08909.x","volume":"89","author":"E. Hellstr\u00f6m-Lindberg","year":"1995","unstructured":"Hellstr\u00f6m-Lindberg E: Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995, 89:67\u201371.","journal-title":"Br J Haematol"},{"key":"1_CR19","doi-asserted-by":"crossref","unstructured":"A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br J Haematol 1998, 103:1070\u20131074.","DOI":"10.1046\/j.1365-2141.1998.01085.x"},{"key":"1_CR20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1046\/j.1365-2141.1997.4013211.x","volume":"99","author":"E. Hellstr\u00f6m-Lindberg","year":"1997","unstructured":"Hellstr\u00f6m-Lindberg E, Negrin R, Stein R, et al.: Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997, 99:344\u2013351.","journal-title":"Br J Haematol"},{"key":"1_CR21","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.22343","volume":"107","author":"P. Giraldo","year":"2006","unstructured":"Giraldo P, Nomdedeu B, Loscertales J, et al.: Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. Cancer 2006, 107:2807\u20132816.","journal-title":"Cancer"},{"key":"1_CR22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2141.2007.06546.x","volume":"137","author":"A.R. Golshayan","year":"2007","unstructured":"Golshayan AR, Jin T, Maciejewski J, et al.: Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. Br J Haematol 2007, 137:125\u2013132.","journal-title":"Br J Haematol"},{"key":"1_CR23","doi-asserted-by":"crossref","first-page":"979","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00008","volume":"142","author":"A. Gafter-Gvili","year":"2005","unstructured":"Gafter-Gvili A, Fraser A, Paul M, Leibovici L: Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005, 142:979\u2013995.","journal-title":"Ann Intern Med"},{"key":"1_CR24","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","volume":"355","author":"A. List","year":"2006","unstructured":"List A, Dewald G, Bennett J, et al.: Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355:1456\u20131465.","journal-title":"N Engl J Med"},{"key":"1_CR25","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood-2007-01-068833","volume":"111","author":"A. Raza","year":"2008","unstructured":"Raza A, Reeves JA, Feldman EJ, et al.: Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008, 111:86\u201393.","journal-title":"Blood"},{"key":"1_CR26","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"L.R. Silverman","year":"2002","unstructured":"Silverman LR, Demakos EP, Peterson BL, et al.: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429\u20132440.","journal-title":"J Clin Oncol"},{"key":"1_CR27","first-page":"250a","volume":"110","author":"P. Fenaux","year":"2007","unstructured":"Fenaux P, Mufti GJ, Santini V, et al.: Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): results of the AZA-001 phase III study [abstract 817]. Blood (ASH Annual Meeting Abstracts) 2007, 110:250a.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"1_CR28","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","volume":"106","author":"H. Kantarjian","year":"2006","unstructured":"Kantarjian H, Issa JP, Rosenfeld CS, et al.: Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1794\u20131803.","journal-title":"Cancer"},{"key":"1_CR29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2141.1990.tb02558.x","volume":"74","author":"T. Witte De","year":"1990","unstructured":"De Witte T, Zwaan F, Hermans J, et al.: Allogeneic bone marrow transplantation for secondary leukemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 1990, 74:151\u2013155.","journal-title":"Br J Haematol"},{"issue":"Suppl1","key":"1_CR30","first-page":"S25","volume":"12","author":"F.R. Appelbaum","year":"1998","unstructured":"Appelbaum FR, Anderson J: Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 1998, 12(Suppl 1):S25\u2013S29.","journal-title":"Leukemia"},{"key":"1_CR31","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","volume":"104","author":"C.S. Cutler","year":"2004","unstructured":"Cutler CS, Lee SJ, Greenberg P, et al.: A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004, 104:579\u2013585.","journal-title":"Blood"},{"key":"1_CR32","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.2006.09.7865","volume":"25","author":"M.L. Sorror","year":"2007","unstructured":"Sorror ML, Sandmaier BM, Storer BE, et al.: Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007, 25:4246\u20134254.","journal-title":"J Clin Oncol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-009-0001-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-009-0001-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-009-0001-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T02:03:30Z","timestamp":1589421810000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-009-0001-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,24]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["1"],"URL":"https:\/\/doi.org\/10.1007\/s11899-009-0001-x","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,24]]}}}